16 Jul, 08:59 - Indian

SENSEX 80664.86 (0.00)

Nifty 50 24586.7 (0.00)

Nifty Bank 52455.9 (0.00)

Nifty IT 38911.35 (0.00)

Nifty Midcap 100 57664.45 (0.00)

Nifty Next 50 74367.35 (0.00)

Nifty Pharma 20844.55 (0.00)

Nifty Smallcap 100 19047.7 (0.00)

16 Jul, 08:59 - Global

NIKKEI 225 41374.3 (0.45)

HANG SENG 17784.69 (-1.28)

DOW JONES 40211.72 (0.53)

S&P 5631.22 (0.28)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(15 Jun 2024, 16:32)

Biocon’s Andhra Pradesh facility gets 3 USFDA observations

Biocon said that US Food and Drug Administration (USFDA) issued three observations after the good manufacturing practices (GMP) inspection conducted at its API manufacturing facility situated at Visakhapatnam, Andhra Pradesh.


The good manufacturing practices was conducted on 14 June 2024 and closed the inspection with three observations. The company said that it will respond to the USFDA within the stipulated timeframe.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported 56.74% decline in consolidated net profit to Rs 135.5 crore despite of 3.79% rise in revenue from operations...

More News
More Company News